UniProtKB/Swiss-Prot P08514 : Variant p.Gln778Pro
Integrin alpha-IIb
Gene: ITGA2B
Feedback ?
Variant information
Variant position:
778
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Glutamine (Q) to Proline (P) at position 778 (Q778P, p.Gln778Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and polar (Q) to medium size and hydrophobic (P)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In GT1; type II.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
778
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
1039
The length of the canonical sequence.
Location on the sequence:
NSQNPNSKIVLLDVPVRAEA
Q VELRGNSFPASLVVAAEEGE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human NSQNPNSKIVLLDVPVRAEAQ VELRGNSFPASLVVAAEEGE
Mouse NSQNPNSKVVMLPVAIQAEAT VELRGNSFPASLVVAAEEGD
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
32 – 1039
Integrin alpha-IIb
Chain
32 – 887
Integrin alpha-IIb heavy chain
Topological domain
32 – 993
Extracellular
Literature citations
A Gln747-->Pro substitution in the IIb subunit is responsible for a moderate IIbbeta3 deficiency in Glanzmann thrombasthenia.
Tadokoro S.; Tomiyama Y.; Honda S.; Arai M.; Yamamoto N.; Shiraga M.; Kosugi S.; Kanakura Y.; Kurata Y.; Matsuzawa Y.;
Blood 92:2750-2758(1998)
Cited for: VARIANT GT1 PRO-778;
Novel point mutations in the alphaIIb subunit (Phe289-->Ser, Glu324-->Lys and Gln747-->Pro) causing thrombasthenic phenotypes in four Japanese patients.
Ambo H.; Kamata T.; Handa M.; Kawai Y.; Oda A.; Murata M.; Takada Y.; Ikeda Y.;
Br. J. Haematol. 102:829-840(1998)
Cited for: VARIANTS GT1 SER-320; LYS-355 AND PRO-778;
AlphaIIbbeta3 integrin: new allelic variants in Glanzmann thrombasthenia, effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure-function.
Jallu V.; Dusseaux M.; Panzer S.; Torchet M.F.; Hezard N.; Goudemand J.; de Brevern A.G.; Kaplan C.;
Hum. Mutat. 31:237-246(2010)
Cited for: VARIANTS GT1 THR-405; THR-596; ARG-705; PRO-778; PHE-934; LEU-957; MET-982 AND THR-989; CHARACTERIZATION OF VARIANTS GT1 PHE-934 AND LEU-957;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.